Hansoh Pharma Secures NMPA Breakthrough-Therapy Designation for B7-H3 ADC HS-20093 in Metastatic Castration-Resistant Prostate Cancer

Bulletin Express04-29 20:43

Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) announced that China’s National Medical Products Administration (NMPA) has granted Breakthrough-Therapy status to HS-20093, the company’s self-developed B7-H3-targeted antibody-drug conjugate (ADC). Key details:

• Designation date: 29 April 2026. • Candidate: HS-20093 for injection, a B7-H3-targeted ADC. • Proposed indication: Treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients previously exposed to novel endocrine therapy and taxane-based chemotherapy. The Breakthrough-Therapy designation is intended to expedite development and review for innovative drugs addressing serious conditions with unmet clinical need. The announcement underscores Hansoh Pharma’s continued investment in ADC research and its strategic focus on difficult-to-treat oncology indications.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1139317987?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-29 20:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139317987","market":"hk","top_or_hot":-1,"title":"Hansoh Pharma Secures NMPA Breakthrough-Therapy Designation for B7-H3 ADC HS-20093 in Metastatic Castration-Resistant Prostate Cancer","media":"Bulletin Express","content":"<p>Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) announced that China’s National Medical Products Administration (NMPA) has granted Breakthrough-Therapy status to HS-20093, the company’s self-developed B7-H3-targeted antibody-drug conjugate (ADC).  \n   \nKey details:</p>\n<p>• Designation date: 29 April 2026.  \n• Candidate: HS-20093 for injection, a B7-H3-targeted ADC.  \n• Proposed indication: Treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients previously exposed to novel endocrine therapy and taxane-based chemotherapy.  \n   \nThe Breakthrough-Therapy designation is intended to expedite development and review for innovative drugs addressing serious conditions with unmet clinical need. The announcement underscores Hansoh Pharma’s continued investment in ADC research and its strategic focus on difficult-to-treat oncology indications.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hansoh Pharma Secures NMPA Breakthrough-Therapy Designation for B7-H3 ADC HS-20093 in Metastatic Castration-Resistant Prostate Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHansoh Pharma Secures NMPA Breakthrough-Therapy Designation for B7-H3 ADC HS-20093 in Metastatic Castration-Resistant Prostate Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-29 20:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) announced that China’s National Medical Products Administration (NMPA) has granted Breakthrough-Therapy status to HS-20093, the company’s self-developed B7-H3-targeted antibody-drug conjugate (ADC).  \n   \nKey details:</p>\n<p>• Designation date: 29 April 2026.  \n• Candidate: HS-20093 for injection, a B7-H3-targeted ADC.  \n• Proposed indication: Treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients previously exposed to novel endocrine therapy and taxane-based chemotherapy.  \n   \nThe Breakthrough-Therapy designation is intended to expedite development and review for innovative drugs addressing serious conditions with unmet clinical need. The announcement underscores Hansoh Pharma’s continued investment in ADC research and its strategic focus on difficult-to-treat oncology indications.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森制药","start_time":0,"source_url":"","article_id":"1139317987","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139317987","pubTimestamp":1777466622,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) announced that China’s National Medical Products Administration (NMPA) has granted Breakthrough-Therapy status to HS-20093, the company’s...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03692":"翰森制药"},"translate_title":"豪森药业B7-H3 ADC HS-20093治疗转移性去势抵抗性前列腺癌获得NMPA突破性疗法认定","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) announced that China’s National Medical Products Administration (NMPA) has granted Breakthrough-Therapy status to HS-20093, the company’s self-developed B7-H3-targeted antibody-drug conjugate (ADC).  \n   \nKey details:\n• Designation date: 29 April 2026.  \n• Candidate: HS-20093 for injection, a B7-H3-targeted ADC.  \n• Proposed indication: Treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients previously exposed to novel endocrine therapy and taxane-based chemotherapy.  \n   \nThe Breakthrough-Therapy designation is intended to expedite development and review for innovative drugs addressing serious conditions with unmet clinical need. The announcement underscores Hansoh Pharma’s continued investment in ADC research and its strategic focus on difficult-to-treat oncology indications.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"policyRegulatory,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1139317987","isCrawlerRequest":true}